{"protocolSection": {"identificationModule": {"nctId": "NCT03506412", "orgStudyIdInfo": {"id": "18-000044"}, "secondaryIdInfos": [{"id": "R21AG053512", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/R21AG053512"}], "organization": {"fullName": "Mayo Clinic", "class": "OTHER"}, "briefTitle": "Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction", "officialTitle": "A Proof of Concept Study to Determine the Efficacy of Entresto\u2122 in HFpEF Based on Circulating Neprilysin Levels: The Circulating NEP and NEP Inhibition (CNEPi) Study", "acronym": "CNEPi"}, "statusModule": {"statusVerifiedDate": "2022-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-06-25", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2021-03-23", "type": "ACTUAL"}, "completionDateStruct": {"date": "2021-03-23", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-04-11", "studyFirstSubmitQcDate": "2018-04-20", "studyFirstPostDateStruct": {"date": "2018-04-24", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2022-01-06", "resultsFirstSubmitQcDate": "2022-01-06", "resultsFirstPostDateStruct": {"date": "2022-02-04", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-01-06", "lastUpdatePostDateStruct": {"date": "2022-02-04", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Naveen L. Pereira", "investigatorTitle": "Professor of Medicine", "investigatorAffiliation": "Mayo Clinic"}, "leadSponsor": {"name": "Mayo Clinic", "class": "OTHER"}, "collaborators": [{"name": "National Institute on Aging (NIA)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "To determine biomarker responses to Entresto\u2122in patients with Heart Failure with preserved Ejection Fraction (HFpEF) and who have high or low serum neprilysin (NEP) levels.", "detailedDescription": "This is a proof of concept single arm study in which 40 subjects with HFpEF will be assigned to Entresto\u2122 49/51 mg (sacubitril/valsartan) twice-daily for a total duration of up to 5 weeks of treatment. Blood will be drawn prior to and at completion of treatment. The primary endpoint measured is change in biomarkers with Entresto\u2122 administration that reflect NEP activity and myocardial stress (NT pro-ANP, -BNP, -CNP) and drug action (cGMP). This endpoint has been well validated as a measure of Entresto\u2122 drug response."}, "conditionsModule": {"conditions": ["Heart Failure With Preserved Ejection Fraction"], "keywords": ["Heart Failure", "HFpEF", "Entresto\u2122", "Neprilysin", "Diastolic Heart Failure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": "Entresto\u2122 will be administered to subjects with high and low circulating neprilysin (NEP) levels.", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 40, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Low Serum Neprilysin (sNEP) levels", "type": "EXPERIMENTAL", "description": "Subjects with baseline sNEP levels less than or equal to 0.9 ng/ml", "interventionNames": ["Drug: Entresto\u2122 49Mg-51 mg tablet"]}, {"label": "High Serum Neprilysin (sNEP) levels", "type": "EXPERIMENTAL", "description": "Subjects with baseline sNEP greater than or equal to 0.9 ng/ml", "interventionNames": ["Drug: Entresto\u2122 49Mg-51 mg tablet"]}], "interventions": [{"type": "DRUG", "name": "Entresto\u2122 49Mg-51 mg tablet", "description": "Entresto\u2122 49Mg-51 mg will be given twice daily orally for 5 weeks", "armGroupLabels": ["High Serum Neprilysin (sNEP) levels", "Low Serum Neprilysin (sNEP) levels"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Plasma N-terminal Proatrial Natriuretic Peptide (NT proANP)", "description": "Change in plasma NT pro-ANP value levels as measured in pg/mL. NT-pro ANP means N-terminal polypeptide of ANP (atrial natriuretic peptide) precursor. Natriuretic peptides are substances made by the heart. Elevated levels can mean the heart isn't pumping as much blood the body needs.", "timeFrame": "baseline, 5 weeks"}, {"measure": "Change in Plasma N-terminal Pro B-type Natriuretic Peptide (NT-proBNP)", "description": "Change in plasma NT pro-ANP value levels as measured in pg/mL. Natriuretic peptides are substances made by the heart. Two main types of these substances are brain natriuretic peptide (BNP) and N-terminal pro b-type natriuretic peptide (NT-proBNP). Elevated levels can mean the heart isn't pumping as much blood the body needs.", "timeFrame": "baseline, 5 weeks"}, {"measure": "Change in Plasma N-terminal Brain Natriuretic Peptide (BNP)", "description": "Change in plasma BNP biomarker value levels as measured in pg/mL. Brain natriuretic peptide is a hormone secreted by cardiomyocytes in the heart ventricles in response to stretching caused by increased ventricular blood volume. Elevated levels can mean the heart isn't pumping as much blood the body needs.", "timeFrame": "baseline, 5 weeks"}, {"measure": "Change in Plasma Cyclic Guanine Monophosphate (cGMP)", "description": "Change in Plasma cGMP biomarker value levels as measured in nmol/L. Cyclic guanosine monophosphate is a cyclic nucleotide derived from guanosine triphosphate. cGMP acts as a second messenger to tissue and cellular responses.", "timeFrame": "baseline, 5 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria\n\n1. Age \u2265 50 years\n2. LVEF \u2265 45% assessed by echocardiography, nuclear scan, MRI or left ventriculogram within the past 24 months\n3. Current New York Heart Association (NYHA) class 2-4 symptoms of heart failure (HF)\n4. Stable medical therapy for 30 days as defined by:\n\n   1. No addition or removal of ACE, ARB, beta-blockers, calcium channel blockers (CCBs) or aldosterone antagonists\n   2. No change in dosage of ACE, ARBs, beta-blockers, CCBs or aldosterone antagonists of more than 100%\n5. One of the following within the last 24 months\n\n   1. Previous hospitalization for HF with radiographic evidence of pulmonary congestion (pulmonary venous hypertension, vascular congestion, interstitial edema, pleural effusion) or\n   2. Catheterization documented elevated filling pressures at rest (LVEDP\u226515 or PCWP\u226520) or with exercise (PCWP\u226525) or\n   3. Elevated NT-proBNP (\\> 400 pg/ml) or BNP (\\> 200 pg/ml) or\n   4. Echo evidence of diastolic dysfunction / elevated filling pressures (at least two)\n\n   i. E/A \\> 1.5 + decrease in E/A of \\> 0.5 with valsalva\n\nii. Deceleration time \u2264 140 ms\n\niii. Pulmonary vein velocity in systole \\< diastole (PVs\\<PVd) (sinus rhythm)\n\niv. E/e'\u226515\n\nv. Left atrial enlargement (\u2265 moderate)\n\nvi. Pulmonary artery systolic pressure \\> 40 mmHg\n\nvii. Evidence of left ventricular hypertrophy\n\n1. LV mass/BSA \u2265 96 (\u2640) or \u2265 116 (\u2642) g/m2\n2. Relative wall thickness \u2265 0.43 (\u2642 or \u2640) \\[(IVS+PW)/LVEDD\\]\n3. Posterior wall thickness \u2265 0.9 (\u2640) or 1.0 (\u2642) cm\n\nExclusion Criteria\n\n1. History of hypersensitivity or allergy to ACE inhibitors (ACEIs), ARBs, or NEP inhibitors\n2. Known history of angioedema\n3. Previous LVEF \\< 40% at any time\n4. Systolic blood pressure \\< 100 mmHg or \\> 180 mmHg\n5. Current acute decompensated HF (exacerbation of chronic HF manifested by signs and symptoms that may require intravenous therapy)\n6. Unstable angina, myocardial infarction, stroke, transient ischemic attack, or cardiovascular surgery or urgent percutaneous coronary intervention (PCI) within 3 months of screening or elective PCI within 30 days of entry\n7. Significant valvular stenosis or regurgitation (greater than moderate in severity), hypertrophic, restrictive or obstructive cardiomyopathy including amyloidosis, constrictive pericarditis, primary pulmonary hypertension, or biopsy proven active myocarditis\n8. Severe congenital heart disease\n9. History of heart transplant or with LV assist device\n10. Evidence of severe hepatic disease as determined by any one of the following: history of hepatic encephalopathy, history of esophageal varices, or history of porto-caval shunt.\n11. Glomerular filtration rate \\< 20 ml/min/1.73 m2 on most recent clinical laboratories\\*\n12. Serum potassium of \\> 5.5 mEq/dL on most recent clinical laboratories\\*\n13. Concomitant use of aliskiren in patients with diabetes\n14. Currently receiving an investigational drug\n15. Inability to comply with planned study procedures\n16. Female subject who is pregnant or breastfeeding\n\n    * Performed within 90 days of enrollment", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "50 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Naveen L Pereira, MD", "affiliation": "Mayo Clinic", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Mayo Clinic in Rochester", "city": "Rochester", "state": "Minnesota", "zip": "55905", "country": "United States", "geoPoint": {"lat": 44.02163, "lon": -92.4699}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Mayo Clinic Clinical Trials", "url": "https://www.mayo.edu/research/clinical-trials"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Total of 40 subject enrolled. Enrolled subjects were assigned to an arm based on their Baseline serum Neprilysin (sNEP) levels. Baseline sNEP levels were only available for 37 subjects. Data not collected for 3 subjects.", "groups": [{"id": "FG000", "title": "Low Serum Neprilysin (sNEP) Levels", "description": "Subjects with baseline sNEP levels less than or equal to 0.9 ng/ml\n\nEntresto\u2122 49Mg-51 mg tablet: Entresto\u2122 49 Mg-51 mg will be given twice daily orally for 5 weeks"}, {"id": "FG001", "title": "High Serum Neprilysin (sNEP) Levels", "description": "Subjects with baseline sNEP greater than or equal to 0.9 ng/ml\n\nEntresto\u2122 49Mg-51 mg tablet: Entresto\u2122 49 Mg-51 mg will be given twice daily orally for 5 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "19"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "19"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Total of 40 subject enrolled. Enrolled subjects were assigned to an arm based on their Baseline serum Neprilysin (sNEP) levels. Baseline sNEP levels were only available for 37 subjects. Data not collected for 3 subjects.", "groups": [{"id": "BG000", "title": "Low Serum Neprilysin (sNEP) Levels", "description": "Subjects with baseline sNEP levels less than or equal to 0.9 ng/ml\n\nEntresto\u2122 49Mg-51 mg tablet: Entresto\u2122 49Mg-51 mg will be given twice daily orally for 5 weeks"}, {"id": "BG001", "title": "High Serum Neprilysin (sNEP) Levels", "description": "Subjects with baseline sNEP greater than or equal to 0.9 ng/ml\n\nEntresto\u2122 49Mg-51 mg tablet: Entresto\u2122 49Mg-51 mg will be given twice daily orally for 5 weeks"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "37"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "37"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "77.0", "lowerLimit": "72.0", "upperLimit": "86.0"}, {"groupId": "BG001", "value": "74.0", "lowerLimit": "63.0", "upperLimit": "78.0"}, {"groupId": "BG002", "value": "76", "lowerLimit": "71", "upperLimit": "79"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "37"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "17"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "20"}]}]}]}, {"title": "Race and Ethnicity Not Collected", "populationDescription": "Race and Ethnicity were not collected from any participant.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "37"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "37"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Plasma N-terminal Proatrial Natriuretic Peptide (NT proANP)", "description": "Change in plasma NT pro-ANP value levels as measured in pg/mL. NT-pro ANP means N-terminal polypeptide of ANP (atrial natriuretic peptide) precursor. Natriuretic peptides are substances made by the heart. Elevated levels can mean the heart isn't pumping as much blood the body needs.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "pg/mL", "timeFrame": "baseline, 5 weeks", "groups": [{"id": "OG000", "title": "Low Serum Neprilysin (sNEP) Levels", "description": "Subjects with baseline sNEP levels less than or equal to 0.9 ng/ml\n\nEntresto\u2122 49Mg-51 mg tablet: Entresto\u2122 49Mg-51 mg will be given twice daily orally for 5 weeks"}, {"id": "OG001", "title": "High Serum Neprilysin (sNEP) Levels", "description": "Subjects with baseline sNEP greater than or equal to 0.9 ng/ml\n\nEntresto\u2122 49Mg-51 mg tablet: Entresto\u2122 49Mg-51 mg will be given twice daily orally for 5 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "47.4", "lowerLimit": "-4.6", "upperLimit": "129.9"}, {"groupId": "OG001", "value": "46.4", "lowerLimit": "6.4", "upperLimit": "139.5"}]}]}]}, {"type": "PRIMARY", "title": "Change in Plasma N-terminal Pro B-type Natriuretic Peptide (NT-proBNP)", "description": "Change in plasma NT pro-ANP value levels as measured in pg/mL. Natriuretic peptides are substances made by the heart. Two main types of these substances are brain natriuretic peptide (BNP) and N-terminal pro b-type natriuretic peptide (NT-proBNP). Elevated levels can mean the heart isn't pumping as much blood the body needs.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "pg/mL", "timeFrame": "baseline, 5 weeks", "groups": [{"id": "OG000", "title": "Low Serum Neprilysin (sNEP) Levels", "description": "Subjects with baseline sNEP levels less than or equal to 0.9 ng/ml\n\nEntresto\u2122 49Mg-51 mg tablet: Entresto\u2122 49Mg-51 mg will be given twice daily orally for 5 weeks"}, {"id": "OG001", "title": "High Serum Neprilysin (sNEP) Levels", "description": "Subjects with baseline sNEP greater than or equal to 0.9 ng/ml\n\nEntresto\u2122 49Mg-51 mg tablet: Entresto\u2122 49Mg-51 mg will be given twice daily orally for 5 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-11.5", "lowerLimit": "-50.0", "upperLimit": "66.0"}, {"groupId": "OG001", "value": "45.0", "lowerLimit": "-16.0", "upperLimit": "107.0"}]}]}]}, {"type": "PRIMARY", "title": "Change in Plasma N-terminal Brain Natriuretic Peptide (BNP)", "description": "Change in plasma BNP biomarker value levels as measured in pg/mL. Brain natriuretic peptide is a hormone secreted by cardiomyocytes in the heart ventricles in response to stretching caused by increased ventricular blood volume. Elevated levels can mean the heart isn't pumping as much blood the body needs.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "pg/mL", "timeFrame": "baseline, 5 weeks", "groups": [{"id": "OG000", "title": "Low Serum Neprilysin (sNEP) Levels", "description": "Subjects with baseline sNEP levels less than or equal to 0.9 ng/ml\n\nEntresto\u2122 49Mg-51 mg tablet: Entresto\u2122 49Mg-51 mg will be given twice daily orally for 5 weeks"}, {"id": "OG001", "title": "High Serum Neprilysin (sNEP) Levels", "description": "Subjects with baseline sNEP greater than or equal to 0.9 ng/ml\n\nEntresto\u2122 49Mg-51 mg tablet: Entresto\u2122 49Mg-51 mg will be given twice daily orally for 5 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-301.5", "lowerLimit": "-684.0", "upperLimit": "-20.0"}, {"groupId": "OG001", "value": "-100.0", "lowerLimit": "-405.0", "upperLimit": "69.0"}]}]}]}, {"type": "PRIMARY", "title": "Change in Plasma Cyclic Guanine Monophosphate (cGMP)", "description": "Change in Plasma cGMP biomarker value levels as measured in nmol/L. Cyclic guanosine monophosphate is a cyclic nucleotide derived from guanosine triphosphate. cGMP acts as a second messenger to tissue and cellular responses.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "nmol/L", "timeFrame": "baseline, 5 weeks", "groups": [{"id": "OG000", "title": "Low Serum Neprilysin (sNEP) Levels", "description": "Subjects with baseline sNEP levels less than or equal to 0.9 ng/ml\n\nEntresto\u2122 49Mg-51 mg tablet: Entresto\u2122 49Mg-51 mg will be given twice daily orally for 5 weeks"}, {"id": "OG001", "title": "High Serum Neprilysin (sNEP) Levels", "description": "Subjects with baseline sNEP greater than or equal to 0.9 ng/ml\n\nEntresto\u2122 49Mg-51 mg tablet: Entresto\u2122 49Mg-51 mg will be given twice daily orally for 5 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.2", "lowerLimit": "2.4", "upperLimit": "8.5"}, {"groupId": "OG001", "value": "1.0", "lowerLimit": "-0.9", "upperLimit": "6.3"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Adverse Events were collected from baseline to end of study, approximately 5 weeks", "eventGroups": [{"id": "EG000", "title": "Low Serum Neprilysin (sNEP) Levels", "description": "Subjects with baseline sNEP levels less than or equal to 0.9 ng/ml\n\nEntresto\u2122 49Mg-51 mg tablet: Entresto\u2122 49Mg-51 mg will be given twice daily orally for 5 weeks", "deathsNumAffected": 0, "deathsNumAtRisk": 18, "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 0, "otherNumAtRisk": 18}, {"id": "EG001", "title": "High Serum Neprilysin (sNEP) Levels", "description": "Subjects with baseline sNEP greater than or equal to 0.9 ng/ml\n\nEntresto\u2122 49Mg-51 mg tablet: Entresto\u2122 49Mg-51 mg will be given twice daily orally for 5 weeks", "deathsNumAffected": 0, "deathsNumAtRisk": 19, "seriousNumAffected": 0, "seriousNumAtRisk": 19, "otherNumAffected": 0, "otherNumAtRisk": 19}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Naveen L. Pereira, M.D.", "organization": "Mayo Clinic", "email": "Pereira.Naveen@mayo.edu", "phone": "507-284-8612"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2021-03-29", "uploadDate": "2022-01-04T16:52", "filename": "Prot_SAP_000.pdf", "size": 420939}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M27580", "name": "Heart Failure, Diastolic", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000549068", "term": "Sacubitril and valsartan sodium hydrate drug combination"}], "ancestors": [{"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M350410", "name": "Sacubitril and valsartan sodium hydrate drug combination", "asFound": "Soap", "relevance": "HIGH"}, {"id": "M301", "name": "Valsartan", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnAg", "name": "Antihypertensive Agents"}]}}, "hasResults": true}